About Gradient Denervation Technologies
We’re redefining treatment for pulmonary hypertension with next-generation PADN technology.
Gradient Denervation Technologies is a Paris-based medical device company developing a breakthrough treatment for pulmonary hypertension (PH). Our aim is to offer a minimally invasive therapy that uses a targeted approach to ease pressure in the lungs and heart for patients with certain types of pulmonary hypertension.
Built on technology developed at Stanford University, Gradient is initially dedicated to improving care for patients with Group 2 PH, particularly those affected by the more complex form known as CpcPH, a group with limited treatment options today.
Gradient Denervation Technologies
Leadership Team
Martin Grasse
Chief Executive Officer
David Amaoua
Chief Technology Officer
Julie Messer
Chief Operating Officer
Greg Mann
Chief Financial Officer
Gradient Denervation Technologies
Board of Directors
Evan Castiglia
Director
Juan Pablo Mas
Director
Lisa Wipperman Heine
Director
Mano Iyer
Director
Martin Grasse
CEO/Director
Sylvain Sachot, PhD
Director
Dr Swami Gnanashanmugam
Observer/Founder
Stanton Rowe
Director
Grants and Awards
Gradient Denervation Technologies has been awarded three innovation grants supporting the development and validation of the Gradient Denervation System to date. These awards reflect growing recognition of the potential impact of our ultrasound-based PADN therapy in treating pulmonary hypertension.
EIT Health Catapult
2020 winner – Medtech 3rd place
i-Lab 2020
2020 Laureat
Innov’up Leader France 2030 Île-de-France
Award Recipient 2023